Abstract
For decades, we have known that most haematological malignancies have a worse prognosis in older patients. The case is particularly striking for acute myeloid leukaemia, for which the 5-year overall survival drops from 63% (95% CI 58–68) in young adults (15–39 years) to 16% (13–20) for patients aged between 65 and 74 years and 3% (2–5) for those aged 75 years and older. However, several indices indicate survival rates are improving. One of the earliest reported changes in survival trends was seen in patients with diffuse large B-cell lymphoma following the introduction of rituximab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
